Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Vaccine Adjuvants Market, by Type
1.4.2 Europe Vaccine Adjuvants Market, by Administration
1.4.3 Europe Vaccine Adjuvants Market, by Application
1.4.4 Europe Vaccine Adjuvants Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
Chapter 4. Competition Analysis - Global
4.1 KBV Cardinal Matrix
4.2 Recent Industry Wide Strategic Developments
4.2.1 Partnerships, Collaborations and Agreements
4.2.2 Product Launches and Product Expansions
4.2.3 Acquisition and Mergers
4.2.4 Trials and Approvals
4.3 Top Winning Strategies
4.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
4.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements: 2020, Feb – 2023, Oct) Leading Players
4.4 Porter Five Forces Analysis
Chapter 5. Europe Vaccine Adjuvants Market, by Type
5.1 Europe Particulate Market, by Country
5.2 Europe Adjuvant Emulsion Market, by Country
5.3 Europe Pathogen Market, by Country
5.4 Europe Combination Market, by Country
5.5 Europe Others Market, by Country
Chapter 6. Europe Vaccine Adjuvants Market, by Administration
6.1 Europe Intramuscular Market, by Country
6.2 Europe Intranasal Market, by Country
6.3 Europe Oral Market, by Country
6.4 Europe Intradermal Market, by Country
6.5 Europe Others Market, by Country
Chapter 7. Europe Vaccine Adjuvants Market, by Application
7.1 Europe Infectious Diseases Market, by Country
7.2 Europe Cancer Market, by Country
7.3 Europe Others Market, by Country
Chapter 8. Europe Vaccine Adjuvants Market, by Country
8.1 Germany Vaccine Adjuvants Market
8.1.1 Germany Vaccine Adjuvants Market, by Type
8.1.2 Germany Vaccine Adjuvants Market, by Administration
8.1.3 Germany Vaccine Adjuvants Market, by Application
8.2 UK Vaccine Adjuvants Market
8.2.1 UK Vaccine Adjuvants Market, by Type
8.2.2 UK Vaccine Adjuvants Market, by Administration
8.2.3 UK Vaccine Adjuvants Market, by Application
8.3 France Vaccine Adjuvants Market
8.3.1 France Vaccine Adjuvants Market, by Type
8.3.2 France Vaccine Adjuvants Market, by Administration
8.3.3 France Vaccine Adjuvants Market, by Application
8.4 Russia Vaccine Adjuvants Market
8.4.1 Russia Vaccine Adjuvants Market, by Type
8.4.2 Russia Vaccine Adjuvants Market, by Administration
8.4.3 Russia Vaccine Adjuvants Market, by Application
8.5 Spain Vaccine Adjuvants Market
8.5.1 Spain Vaccine Adjuvants Market, by Type
8.5.2 Spain Vaccine Adjuvants Market, by Administration
8.5.3 Spain Vaccine Adjuvants Market, by Application
8.6 Italy Vaccine Adjuvants Market
8.6.1 Italy Vaccine Adjuvants Market, by Type
8.6.2 Italy Vaccine Adjuvants Market, by Administration
8.6.3 Italy Vaccine Adjuvants Market, by Application
8.7 Rest of Europe Vaccine Adjuvants Market
8.7.1 Rest of Europe Vaccine Adjuvants Market, by Type
8.7.2 Rest of Europe Vaccine Adjuvants Market, by Administration
8.7.3 Rest of Europe Vaccine Adjuvants Market, by Application
Chapter 9. Company Profiles
9.1 Novavax, Inc.
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Segmental and Regional Analysis
9.1.4 Research & Development Expenses
9.1.5 Recent strategies and developments:
9.1.5.1 Partnerships, Collaborations, and Agreements:
9.1.6 SWOT Analysis
9.2 SPI Pharma, Inc. (Associated British Foods PLC)
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental and Regional Analysis
9.2.4 Research & Development Expenses
9.2.5 Recent strategies and developments:
9.2.5.1 Partnerships, Collaborations, and Agreements:
9.3 Agenus Inc.
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Regional Analysis
9.3.4 Research & Development Expenses
9.3.5 Recent strategies and developments:
9.3.5.1 Partnerships, Collaborations, and Agreements:
9.3.6 SWOT Analysis
9.4 InvivoGen SAS
9.4.1 Company Overview
9.4.2 SWOT Analysis
9.5 Seppic S.A. (L’Air Liquide S.A.)
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental and Regional Analysis
9.5.4 Research & Development Expenses
9.5.5 Recent strategies and developments:
9.5.5.1 Product Launches and Product Expansions:
9.5.6 SWOT Analysis
9.6 Riboxx GmbH
9.6.1 Company Overview
9.7 GlaxoSmithKline PLC (GSK)
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Regional Analysis
9.7.4 Research & Development Expense
9.7.5 Recent strategies and developments:
9.7.5.1 Partnerships, Collaborations, and Agreements:
9.7.5.2 Product Launches and Product Expansions:
9.7.5.3 Trials and Approvals:
9.7.6 SWOT Analysis
9.8 CSL Limited
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Segmental and Regional Analysis
9.8.4 Research & Development Expenses
9.8.5 Recent strategies and developments:
9.8.5.1 Partnerships, Collaborations, and Agreements:
9.8.6 SWOT Analysis
9.9 Croda International PLC
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Segmental and Regional Analysis
9.9.4 Recent strategies and developments:
9.9.4.1 Partnerships, Collaborations, and Agreements:
9.9.4.2 Acquisition and Mergers:
9.10. Merck & Co., Inc.
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Segmental and Regional Analysis
9.10.4 Research & Development Expenses
9.10.5 Recent strategies and developments:
9.10.5.1 Acquisition and Mergers:
9.10.6 SWOT Analysis
Unique Offerings 